cyclocaric acid A, hederagenin
| Name | Hederagenin | ||
| PubChem CID | 73299 | ||
| Molecular Weight | 472.7g/mol | ||
| Synonyms |
cyclocaric acid A, hederagenin |
||
| Formula | C₃₀H₄₈O₄ | ||
| SMILES | CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)CO)O)C)C)C2C1)C)C(=O)O)C | ||
| InChI | 1S/C30H48O4/c1-25(2)13-15-30(24(33)34)16-14-28(5)19(20(30)17-25)7-8-22-26(3)11-10-23(32)27(4,18-31)21(26)9-12-29(22,28)6/h7,20-23,31-32H,8-18H2,1-6H3,(H,33,34)/t20-,21+,22+,23-,26-,27-,28+,29+,30-/m0/s1 | ||
| InChIKey | PGOYMURMZNDHNS-MYPRUECHSA-N | ||
| CAS Number | 465-99-6 | ||
| ChEMBL ID | CHEMBL486400 | ||
| ChEBI ID | CHEBI:69579 | ||
| Herb ID | HBIN028847 | ||
| Toxicity | Organism | Test Type | Route(Dose) |
| rat | LD50 | intraperitoneal(165 mg/kg) | |
| mouse | LD50 | intraperitoneal(254 mg/kg) | |
| rat | LD50 | oral(322 mg/kg) | |
| Structure | 
|
Download
2D
MOL
3D
MOL
|
|
| Chineses Pinyin | MuTong | ||
| Use Part | Stem | ||
| Habitat | JiangSu, HuNan, HuBei | ||
| Flavor | Bitter | ||
| Meridian Tropism | Heart, Small intestine, Bladder | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Ranunculales
-->Family: Lardizabalaceae
-->Genus: Akebia
-->Species: Akebia quinata
|
||
| Chineses Pinyin | ChangChunTeng | ||
| Use Part | Stem-leaf | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Apiales
-->Family: Araliaceae
-->Genus: Hedera
-->Species: Hedera nepalensis
|
||
| Pair Name | Hederagenin, Cisplatin | |||
| Partner Name | Cisplatin | |||
| Disease Info | Head and neck cancer | / | ||
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Down-regulation | Expression | HMOX1 | hsa3162 | |
| Up-regulation | Expression | KEAP1 | hsa9817 | |
| Down-regulation | Expression | NFE2L2 | hsa4780 | |
| Down-regulation | Expression | NQO1 | hsa1728 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| Down-regulation | Expression | SLC7A11 | hsa23657 | |
| Down-regulation | Expression | SQSTM1 | hsa8878 | |
| Up-regulation | Phosphorylation | TP53 | hsa7157 | |
| In Vitro Model | HN-3 | Tongue squamous cell carcinoma | Homo sapiens (Human) | CVCL_8126 |
| HN-9 | Tongue squamous cell carcinoma | Homo sapiens (Human) | CVCL_8132 | |
| HN3-cisR | Cisplatin-resistant tongue squamous cell carcinoma | Homo sapiens (Human) | N.A. | |
| HN9-cisR | Cisplatin-resistant tongue squamous cell carcinoma | Homo sapiens (Human) | N.A. | |
| In Vivo Model | HN9-cisR cells were subcutaneously injected into the flank of nude mice. Beginning on the first day gross nodules from tumor implants were detected, the mice began receiving intraperitoneal injections of the vehicle control or hederagenin (50, 100, or 200 mg/kg daily). Each treatment group included 10 mice. | |||
| Result | Hederagenin effectively targets cisplatin-resistant HNC cells in vitro and in vivo. Consistent with its effects in other types of cancer, hederagenin markedly induces apoptosis in HNC cells by activating the mitochondria-driven intrinsic apoptotic pathway. We demonstrated that the apoptosis-inducing effects of hederagenin are mediated by the inhibition of the Nrf2-ARE antioxidant pathway. | |||
